(No ratings)
Dr. Mark D. Fleming, MD, DPhil is a hematopathologist in Boston, MA specializing in hematopathology. He graduated from Harvard Medical School. Dr. Mark D. Fleming, MD, DPhil is affiliated with Dana-Farber Cancer Institute and Boston Children's Hospital.
Anemia
Anemia is the most common blood disorder. It occurs when the body does not have enough red blood cells to carry oxygen to the tissues. Blood loss, insufficient red blood cell production, and red blood cell destruction are the three main causes of anemia. These issues may arise from such conditions as iron deficiency, heavy periods, ulcers, kidney disease, as well as some forms of cancer.
An individual with anemia will have the following symptoms: shortness of breath, weakness, dizziness, cold hands or feet, paleness, and irritability. Anemia is diagnosed when blood tests show low counts for hemoglobin, which is the protein responsible for carrying oxygen to different tissues throughout the body.
Treatments for anemia are dependent on the kind of anemia an individual has. For example, iron supplementation may correct iron deficiency anemia. For anemia caused by chronic kidney failure, chemotherapy treatments, and HIV/AIDS, a group of medications called erythropoiesis-stimulating agents may be prescribed.
Dr. Mark D. Fleming, MD, DPhil graduated from Harvard Medical School. He completed residency at Brigham and Women's Hospital. He is certified by the Board Certification:Hematopathology and has a state license in Massachusetts.
Medical School: Harvard Medical School
Residency: Brigham and Women's Hospital
Board Certification: Board Certification:Hematopathology
Licensed In: Massachusetts
Dr. Mark D. Fleming, MD, DPhil is associated with these hospitals and organizations:
Dr. Mark D. Fleming, MD, DPhil does not have any reviews yet, be the first to leave a review of Dr. Mark D. Fleming, MD, DPhil here: Leave a Review
(No ratings)
These charts describe general payments received by Dr. Mark D. Fleming, MD, DPhil. Doctors may receive payments for a number of reasons, including meal compensation, travel compensation, and consulting.
| Millennium Pharmaceuticals, Inc. |
$26,375
$26,375 |
|||
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated |
$13,500
$13,500 |
|||
| Novartis Pharmaceuticals Corporation |
$3,200
$3,200 |
|||
| Takeda Pharmaceuticals U.S.A., Inc. |
$1,500
$1,500 |
|||
| Luitpold Pharmaceuticals Inc |
$700
$700 |
|||
| Other |
$837
CEREC $448 |
Irrisept $163 |
ENTRE $153 |
ALPROLIX $73 |
| Consulting Fee | $45,275 |
|---|---|
| Food and Beverage | $837 |
Dr. Mark D. Fleming, MD, DPhil has received 3 research payments totaling $204,700.
Dr. Mark Fleming is a specialist in hematopathology. He works in Boston, MA. His education and training includes medical school at Harvard Medical School and residency at Brigham and Women's Hospital. Dr. Fleming is professionally affiliated with Dana-Farber Cancer Institute.